Preimplantation Genetic Testing Market to Reach USD 465.1 Million by 2026 at a CAGR of 8.7%
Tags: Marketing Strategies, Straits Research, Market Research Reports, Market, Genetic Testing

Preimplantation Genetic Testing Market to Reach USD 465.1 Million by 2026 at a CAGR of 8.7% Akankshastraitsresearch Dec 22, 2021·3 min read

Increasing awareness about pregnancy & childbirth, aging & menopause, fertility management, and sexual health worldwide are primary factors driving the demand for PGT. Moreover, an increase in the adoption of IVF procedures can be seen as a result of late marriages, infertility, and growing ambitious population in the developing regions. One in each four couples in the developing countries is affected by infertility. Moreover, PGD benefits the couples suffering from hereditary disorders, which, in turn, is driving demand for preimplantation genetic testing. With increasing infertility in men, some of the start-ups are helping males in solving their erectile-dysfunction predicament by providing appropriate drugs online.

Increasing Initiatives to Promote Healthy Pregnancies

Preimplantation genetic testing, by type, is segmented into the preimplantation genetic screening, preimplantation genetic diagnosis.

PGD segment is accounting for the largest market share during the forecast period. Moreover, increasing government efforts to support healthy pregnancies are progressing the market. For instance, in 2017, the Switzerland government passed a medial law to allow pre-implantation genetic diagnosis. As per Switzerland government, around 500–1,000 couples every year undergo IVF treatment. Moreover, to lessen the burden on families and to promote IVF in developing countries, many banks provide EMI’s for treatment. For instance, in india, Bajaj Finance offer lifecare maternity care and IVF treatment. It is available in 400 cities and in partnership with over 2700 hospitals to cover a wide population.

Product & service segment is divided into reagents & consumables, instruments, and software & services. The reagents & consumables segment is generating the highest revenue following increasing applications of diagnostic technologies.

Currently, Asia Pacific is witnessing significant growth in infertility rate. Late marriages, rising number of singles, preference for no children, and higher divorce rates are major factors affecting the fertility. According to the Indian Society of Assisted Reproduction, infertility affects about 10%-14% of the Indian population. Moreover, in Australia and New Zealand, 1 in 6 couples suffers from infertility, Fertility Society of Australia. Apart from this, the Australian government is providing infertile couples with insurance coverage to promote the benefits of IVFin the region. Japan, Singapore, and South Korea’s total fertility rate have been plummeted to 1.44, 1.20, and 1.17, respectively, the World Bank. Hong Kong has one of the lowest fertility rates in the world, which is adding fuel to the demand for PGT and IVF in this region. In India, data-driven fertility program Elawoman has raised USD 3 million in funding by Chiratae Ventures.

The Middle East and Africa are offering significant growth opportunities in the global preimplantation genetic testing market. Moreover, the outbreak of zika virus in Africa has increased the cases of preterm birth, miscarriages, and microcephaly. In the Middle East, congenital malformations are one of the leading causes of infant mortality, WHO.

Competitive Landscape

Several key players are taking continuous efforts for developing innovative products and expanding market presence.

In 2018, Natera, a prominent leader in non-invasive genetic testing, shared a study on spectrum preimplantation genetic screening, innovative technology to improve IVF outcomes. Spectrum PGT-A is found to reduce the negative risks for IVF by allowing only suitable embryos.

In 2018, Illumina Inc. entered into an agreement with Vitrolife AB. In this, Vitrolife will distribute Illumina’s PGT products in America and EMEA.

Some of the other players active in the market are Illumina, Inc, SciGene Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Yikon Genomics.

Preimplantation Genetic Testing Market Segmentation

By Procedure Type

Preimplantation Genetic Screening

Preimplantation Genetic Diagnosis

By Technology

Next-Generation Sequencing

Polymerase Chain Reaction

Fluorescence in Situ Hybridization

Comparative Genomic Hybridization

Single-Nucleotide Polymorphism

By Product and Service

Reagents and Consumables

Instruments

Software and Services

By Application

Aneuploidy Screening

Structural Chromosomal Abnormalities

Translocations

Deletions

Duplications

Inversions

X-Linked Disorders

HLA Typing

Single Gene Disorder Screening

Gender Identification

By End User

Hospitals

Diagnostic Laboratories

Research & Academic Centers

Fertility Clinics & Maternity Centers

Regions Covered

America

North America

U.S.

Canada

Mexico

South America

Europe

Western Europe

UK

Germany

France

Italy

Spain

Rest of Europe

Eastern Europe

Asia-Pacific

China

India

Japan

South Korea

Australia

Rest of Asia-Pacific

MEA

The Middle East

Saudi Arabia

UAE

Qatar

Rest of The Middle East

Africa

Key Players